Effect of rioprostil, an oral prostaglandin E1 (PGE1) analogue, on lower esophageal sphincter pressure and on the motility of the distal esophagus in healthy volunteers.
The influence of rioprostil on the resting pressure of the lower esophageal sphincter (LESP) and on the bolus-stimulated contraction wave amplitude of primary peristalsis was investigated in 9 healthy male volunteers receiving placebo or 300 and 600 micrograms of rioprostil orally in a randomised, double-blind, threefold cross over study. Manometry was performed using the low-compliance pneumohydraulic infusion system. Rioprostil in a dose of 600 micrograms slightly increased LESP and contraction wave amplitudes measured 5 cm and 10 cm above LES. The duration of the peristaltic contractions was not altered. We conclude that rioprostil in doses which inhibit effectively gastric acid and pepsin secretion and heal peptic ulcers has no inhibitory effects on esophageal motility. Thus rioprostil may be a candidate to treat reflux esophagitis and studies are warranted to establish its efficacy.
Baunack
A R
AR
Pharmaceutical Research Centre, Department of Medicine, Bayer AG, Wuppertal, F.R.G.
Froese
G
G
Demol
P
P
Wargenau
M
M
Ruoff
H J
HJ
Weihrauch
T R
TR
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004943:Esophagogastric Junction / Q000187:drug effects*; D006801:Humans; D008297:Male; D008365:Manometry; D010528:Peristalsis / Q000187:drug effects; D011458:Prostaglandins E / Q000494:pharmacology*; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*; D011897:Random Allocation; D016630:Rioprostil
D000897:Anti-Ulcer Agents; D011458:Prostaglandins E; D011459:Prostaglandins E, Synthetic; D016630:Rioprostil